SPARC drops as Q2 net loss widens to Rs 107 crore

Net sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024.

Total expenses rose 3.43% YoY to Rs 120.07 crore in September 2024 quarter.

Employee benefit expenses stood at Rs 38.48 crore (up 25.3% YoY), professional charges were at Rs 30.75 crore (down 26.58% YoY), clinical trial expenses at Rs 25.53 crore (up 40.2% YoY).

On half yearly basis, the firm reported net loss of Rs 204.44 crore in H1 FY25 as against net loss of Rs 181.09 crore in H1 FY24. Net sales decreased 34.26% YoY to Rs 29.67 crore in H1 FY25.

Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.